NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder

CompletedPhase 3

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions: Major Depressive Disorder

Interventions: Antidepressant + Placebo, Antidepressant + Aripiprazole

Countries: United States

This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Men and women, 18-65 years old
* Experienced a Major Depressive Disorder with the current episode of minimally 8 weeks in duration.
* Treatment history of an inadequate response to at least one and no more than three antidepressants.

Locations (28)

Beverly Hills, California, United States
Burbank, California, United States
National City, California, United States
Orange, California, United States
Pasadena, California, United States
Denver, Colorado, United States
Farmington, Connecticut, United States
Jacksonville, Florida, United States
Orlando, Florida, United States
Atlanta, Georgia, United States
Rockville, Maryland, United States
Albuquerque, New Mexico, United States
Brooklyn, New York, United States
New York, New York, United States
Cincinnati, Ohio, United States
Toledo, Ohio, United States
Portland, Oregon, United States
Pittsburgh, Pennsylvania, United States
Memphis, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
Arlington, Virginia, United States
Herndon, Virginia, United States
Richmond, Virginia, United States
Bellevue, Washington, United States
Seattle, Washington, United States
Brown Deer, Wisconsin, United States
Middleton, Wisconsin, United States